Skip to main content

Table 2 Patient characteristics (n = 28)

From: Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST

Characteristics

Nb (%)

Sex

 Male (%)

18 (64)

 Female (%)

10 (36)

Age (median, range), years

63 (42–79)

Tobacco use (%)

23 (82)

Histologya

 Adenocarcinoma (%)

21 (75)

 Squamous cell carcinoma (%)

4 (14)

 Large cell carcinoma (%)

1 (4)

 Large cell neuroendocrine carcinoma (%)

1 (4)

 Lymphoepithelioma-like carcinoma (%)

1 (4)

Previous lines of chemotherapy (median, range)

2 (1–5)

Previous thoracic surgery

5 (18)

No. of nivolumab cycles (median, range)

11 (4–27)

  1. aAccording to the 2015 World Health Organization Classification of Lung Tumors [26]